Published in Clin Genet on March 01, 1989
Strength characterization of knee flexor and extensor muscles in Prader-Willi and obese patients. BMC Musculoskelet Disord (2009) 0.99
Normal size of hands and feet in Prader-Willi syndrome. Clin Genet (1990) 0.75
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
A global profile of germline gene expression in C. elegans. Mol Cell (2000) 5.97
The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. Am J Med Genet (1988) 4.84
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature (1988) 3.90
A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet (2001) 3.59
The cellular immune response to primary sarcomata in rats. II. Abnormal responses of nodes draining the tumour. Proc R Soc Lond B Biol Sci (1969) 3.54
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 3.45
The immediate effect of antigens on the cell output of a lymph node. Br J Exp Pathol (1965) 3.16
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet (1996) 3.08
The distal arthrogryposes: delineation of new entities--review and nosologic discussion. Am J Med Genet (1982) 3.06
Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol (1999) 3.01
The ultrastructure and function of the cells in lymph following antigenic stimulation. J Exp Med (1967) 2.98
Clinical and molecular cytogenetic characterisation of a newly recognised microdeletion syndrome involving 2p15-16.1. J Med Genet (2006) 2.97
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
Intrinsic rhythmic propulsion of lymph in the unanaesthetized sheep. J Physiol (1965) 2.87
The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet (1997) 2.84
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
Physicians' willingness to participate in the process of lethal injection for capital punishment. Ann Intern Med (2001) 2.66
A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 2.65
Studies on the lymphocytes of sheep. III. Destination of lymph-borne immunoblasts in relation to their tissue of origin. Eur J Immunol (1977) 2.61
Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet (1992) 2.53
The distribution and differentiation of lymph-borne immunoblasts after intravenous injection into syngeneic recipients. Cell Tissue Kinet (1972) 2.52
Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med (1980) 2.50
Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet (1998) 2.42
Studies of the cells in the afferent and efferent lymph of lymph nodes draining the site of skin homografts. J Exp Med (1967) 2.31
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Chromosome maps of man and mouse. IV. Ann Hum Genet (1989) 2.25
Noonan syndrome: the changing phenotype. Am J Med Genet (1985) 2.24
Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem (1998) 2.23
Familial insertional translocation of a portion of 3q into 11q resulting in duplication and deletion of region 3q22.1 leads to q24 in different offspring. Am J Med Genet (1981) 2.23
Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG)n. Nucleic Acids Res (1990) 2.23
Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS (2000) 2.19
Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature (1985) 2.19
Evidence for multi-site closure of the neural tube in humans. Am J Med Genet (1993) 2.16
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet (1999) 2.12
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol (1999) 2.10
HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet (1997) 2.09
Errors of morphogenesis: concepts and terms. Recommendations of an international working group. J Pediatr (1982) 2.04
Physicians' attitudes about involvement in lethal injection for capital punishment. Arch Intern Med (2000) 2.04
Congenital hypothalamic hamartoblastoma, hypopituitarism, imperforate anus and postaxial polydactyly--a new syndrome? Part I: clinical, causal, and pathogenetic considerations. Am J Med Genet (1980) 2.02
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet (1999) 2.02
Terathanasia, folic acid, and birth defects. Lancet (1997) 2.00
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest (2000) 1.98
Genetic counseling for adoptees at risk for specific inherited disorders. Am J Med Genet (1980) 1.98
The cellular immune response to primary sarcomata in rats. I. The significance of large basophilic cells in the thoracic duct lymph following antigenic challenge. Proc R Soc Lond B Biol Sci (1969) 1.97
A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet (1994) 1.97
The frequency and financial burden of genetic disease in a pediatric hospital. Am J Med Genet (1978) 1.97
Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci (2000) 1.92
Limb pterygium syndromes: a review and report of eleven patients. Am J Med Genet (1982) 1.91
The homing of lymph-borne immunoblasts to the small gut of neonatal rats. Transplantation (1972) 1.89
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia (2010) 1.87
The transport by hepatocytes of immunoglobulin A from blood to bile visualized by autoradiography and electron microscopy. Immunology (1979) 1.86
Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Hum Mol Genet (1997) 1.82
Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem (2000) 1.79
An invasive cleavage assay for direct quantitation of specific RNAs. Nat Biotechnol (2001) 1.79
Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ (1998) 1.76
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Amyoplasia, the most common type of arthrogryposis: the potential for good outcome. Pediatrics (1996) 1.75
Opinion: predictive testing for Huntington disease in childhood: challenges and implications. Am J Hum Genet (1990) 1.75
Osteogenesis imperfecta type II delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet (1984) 1.72
Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation (2001) 1.71
First-trimester prenatal diagnosis for Huntington's disease with DNA probes. Lancet (1987) 1.70
Confidentiality and health insurance fraud. Arch Intern Med (1997) 1.68
Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem (1999) 1.66
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer (2013) 1.65
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation (2000) 1.65
Evidence from family studies that the gene causing Huntington disease is telomeric to D4S95 and D4S90. Am J Hum Genet (1989) 1.64
X-linked cutis laxa: defective cross-link formation in collagen due to decreased lysyl oxidase activity. N Engl J Med (1980) 1.62
Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res (2001) 1.62
DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet (1987) 1.61
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J (2011) 1.60
Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program. Am J Med Genet (1993) 1.59
Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet (2003) 1.58
Evidence for a primary association between immunoblasts and small gut. Nature (1972) 1.56
Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum Mol Genet (1995) 1.55
A method for collecting lymph from the prefemoral lymph node of unanaesthetised sheep. Q J Exp Physiol Cogn Med Sci (1967) 1.54
HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem (2001) 1.54
Germinal mosaicism in Duchenne muscular dystrophy. Hum Genet (1988) 1.54
Noonan phenotype associated with neurofibromatosis. Am J Med Genet (1985) 1.53
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A (2001) 1.51
Transformation, in vivo, of basophilic lymph cells into plasma cells. Nature (1967) 1.49
Genomic imprinting, monozygous twinning, and X inactivation. Lancet (1991) 1.47
Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem (1996) 1.47
Thrombocytopenia and absent radius (TAR) syndrome. J Med Genet (1987) 1.47
IgA antibodies in the bile of rats. I. Some characteristics of the primary response. Immunology (1982) 1.46
Genetic aspects of arthrogryposis. Clin Orthop Relat Res (1985) 1.46
Genetic linkage between Huntington disease and the D4S10 locus in South African families: further evidence against non-allelic heterogeneity. Hum Genet (1991) 1.46
Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet (1989) 1.46
Homing of lymph-borne immunoblasts to the gut. Nature (1970) 1.45
Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ (2004) 1.44
Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. Clin Pharmacol Ther (2010) 1.44